Ryder System, Inc. (R)

NYQ – Real vaqt narxi. Valyuta: USD

227.76

-4.71 (-2.03%)

Yopilishda: May 12, 2026, 4:00 PM EDT

227.76

0.00 (0.00%)

Bozor oldidan: May 13, 2026, 7:16 AM EDT

12.05.2026

Ryder System, Inc. (R) Presents at Bank of America 33rd Annual Industrials, Transportation and Airlines Key Leaders Conference Transcript

12.05.2026

BioInvent's TNFR2 Antibody BI-1808 Shows Strong Activity and Immune Activation as Single Agent and in Combination with KEYTRUDA(R) (pembrolizumab) in Advanced CTCL (EHA 2026)

40% objective response rate ( ORR) as single agent in heavily pre - treated patients with advanced Cutaneous T-Cell Lymphoma (CTCL) Durable responses observed, including a complete response lasting over two years and ongoing 50% ORR in combination with KEYTRUDA® (pembrolizumab) Targeting TNFR2 drove robust immune activation, with depletion of regulatory T cells and increased CD8+ T cell infiltration in skin lesions Early immune - related skin reactions - "flares"- correlated with biological activity and immune remodeling Favorable safety profile with mostly mild to moderate treatment - related adverse events LUND, SE / ACCESS Newswire / May 12, 2026 / BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV)(STO:BINV), a leader in the discovery of novel immune-modulatory antibodies, today announced that new clinical data from its ongoing Phase 2a trial evaluating BI-1808, its novel anti-TNFR2 monoclonal antibody, in patients with advanced CTCL will be presented at the upcoming European Hematology Association (EHA) 2026 Congress in Stockholm, Sweden. The data underscore BI-1808's potential as both a single agent and combination therapy in this difficult-to-treat cancer with limited therapeutic options.

$BioInvent to Present Clinical Data on FcγRIIB Antibody BI-1206 Triplet Combination Therapy with rituximab and Calquence(R) in Relapsed/Refractory NHL at EHA 2026$

12.05.2026

BioInvent to Present Clinical Data on FcγRIIB Antibody BI-1206 Triplet Combination Therapy with rituximab and Calquence(R) in Relapsed/Refractory NHL at EHA 2026

LUND, SE / ACCESS Newswire / May 12, 2026 / BioInvent International (STO:BINV) - BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a leader in the discovery of novel immune-modulatory antibodies, today announced that it has been selected for a poster presentation of the BI-1206 triplet combination in relapsed/refractory non-Hodgkin's lymphoma (NHL) at the 31st European Hematology Association (EHA2026) Congress, taking place June 11-14, 2026 in Stockholm, Sweden. Poster Presentation Title: Targeting resistance to rituximab through FcγRIIB (CD32B) blockade: BI-1206 + rituximab + acalabrutinib shows powerful activity in R/R NHL Presenter: Dr. Laura Fogliatto, Hospital de Clínicas de Porto Alegre, Brazil Session Date/Time: Friday, June 12, 6:45 pm-7:45 pm CEST (12:45 pm-1:45 pm EDT) Location: EHA2026 Congress, Stockholm The presentation will summarize emerging efficacy and safety observations and mechanistic insights from the ongoing Phase 1/2 study (NCT03571568) evaluating BI-1206 in combination with rituximab and Calquence® (acalabrutinib) in patients with relapsed or refractory NHL, including follicular lymphoma.

12.05.2026

Ensysce Biosciences Announces Expansion of Patent Protection for Groundbreaking MPAR(R) Overdose Protection Technology

~ Patent Extends Jurisdiction and Protection Through 2042 ~ SAN DIEGO, CA / ACCESS Newswire / May 12, 2026 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company pioneering next-generation pain and central nervous system therapeutics designed to minimize abuse and overdose risk, today announced that the Taiwan Intellectual Property Office issued a patent covering Ensysce's MPAR® (Multi-Pill Abuse Resistance) technology. The patent, titled "Compositions Comprising Enzyme-Cleavable Prodrugs and Controlled Release Nafamostat and Methods of Use Thereof", includes both composition-of-matter and method-of-use claims that strengthen Ensysce's intellectual property estate for its unique overdose protection platform.

12.05.2026

Quarterly Report Q1 2026: Orviglance(R) Approaching Transformative Milestones

MALMÖ, SE / ACCESS Newswire / May 12, 2026 / Ascelia Pharma AB (publ) (STO:ACE) today published its Interim Report Q1 for 2026 (January - March), which is now available on the company's website: Financial Reports - ASCELIA KEY EVENTS IN Q1 2026 Abstract with Orviglance data has been accepted for oral presentation at the annual radiology congress ESGAR 2026 Management changes: Anton Hansson starts as CFO, while Julie Waras Brogren leaves her position as Deputy CEO KEY EVENTS AFTER THE PERIOD Ascelia Pharma completes directed share issue of SEK 20 million before transaction costs FINANCIAL SUMMARY Q1 (Jan-Mar) 2026 Operating result of SEK -17.2M (SEK -20.3M) Earnings per share of SEK -0.13 (SEK -0.23) Cash flow from operations of SEK -15.9M (SEK -16.9M) Liquid assets and marketable securities of SEK 33.9M (SEK 57.3M) "Orviglance® is on track for approval on the July 3 PDUFA date. FDA's review of our New Drug Application (NDA) progressed as planned during the quarter, and we remain fully engaged in a constructive, transparent dialogue with the agency as we approach the final month of the review.

05.05.2026

Theralase(R) Announces $4 Million Brokered LIFE Offering

THIS NEWS RELEASE IS NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES Toronto, Ontario--(Newsfile Corp. - May 5, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to the research and development of energy-activated small molecules for the safe and effective destruction of cancer, bacteria and viruses is pleased to announce that it has entered into an agreement with Research Capital Corporation ("RCC" or the "Agent") to act as the sole agent and sole bookrunner on a commercially reasonable "best efforts" agency basis for a brokered private placement offering ("Offering") of units of the Company ("Units") at a price of C$0.24 per Unit, to raise a minimum of C$3,000,000 and up to a maximum of C$4,000,000 in aggregate gross proceeds. Each Unit will consist of one common share of the Company ("Common Share") and one Common Share purchase warrant ("Warrant").

05.05.2026

Ryder CEO to Address Bank of America Securities Industrials, Transportation, and Airlines Key Leaders Conference

MIAMI--(BUSINESS WIRE)-- #RyderEverbetter--Ryder System, Inc. (NYSE: R) Chief Executive Officer John Diez will present a company update at the 2026 Bank of America Securities Industrials, Transportation, and Airlines Key Leaders Conference. Who: Ryder System, Inc. Chief Executive Officer John Diez What: Bank of America Securities Industrials, Transportation, and Airlines Key Leaders Conference When: Tuesday, May 12, 2026 Time: 11:05 a.m. Eastern Time Webcast: To access the link to the live webcast, visit: Ryder.

Videolar

No Data

There is no data to display

Press-relizlar

12.05.2026

BioInvent's TNFR2 Antibody BI-1808 Shows Strong Activity and Immune Activation as Single Agent and in Combination with KEYTRUDA(R) (pembrolizumab) in Advanced CTCL (EHA 2026)

12.05.2026

Ensysce Biosciences Announces Expansion of Patent Protection for Groundbreaking MPAR(R) Overdose Protection Technology

12.05.2026

Quarterly Report Q1 2026: Orviglance(R) Approaching Transformative Milestones

05.05.2026

Ryder System, Inc. (R)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Ryder System, Inc. (R)

Ryder System, Inc. (R) Presents at Bank of America 33rd Annual Industrials, Transportation and Airlines Key Leaders Conference Transcript

BioInvent's TNFR2 Antibody BI-1808 Shows Strong Activity and Immune Activation as Single Agent and in Combination with KEYTRUDA(R) (pembrolizumab) in Advanced CTCL (EHA 2026)

BioInvent to Present Clinical Data on FcγRIIB Antibody BI-1206 Triplet Combination Therapy with rituximab and Calquence(R) in Relapsed/Refractory NHL at EHA 2026

Ensysce Biosciences Announces Expansion of Patent Protection for Groundbreaking MPAR(R) Overdose Protection Technology

Quarterly Report Q1 2026: Orviglance(R) Approaching Transformative Milestones

Theralase(R) Announces $4 Million Brokered LIFE Offering

Ryder CEO to Address Bank of America Securities Industrials, Transportation, and Airlines Key Leaders Conference

Videolar

No Data

Press-relizlar

BioInvent's TNFR2 Antibody BI-1808 Shows Strong Activity and Immune Activation as Single Agent and in Combination with KEYTRUDA(R) (pembrolizumab) in Advanced CTCL (EHA 2026)

Ensysce Biosciences Announces Expansion of Patent Protection for Groundbreaking MPAR(R) Overdose Protection Technology

Quarterly Report Q1 2026: Orviglance(R) Approaching Transformative Milestones

Theralase(R) Announces $4 Million Brokered LIFE Offering

Ryder System, Inc. (R) Presents at Bank of America 33rd Annual Industrials, Transportation and Airlines Key Leaders Conference Transcript

BioInvent's TNFR2 Antibody BI-1808 Shows Strong Activity and Immune Activation as Single Agent and in Combination with KEYTRUDA(R) (pembrolizumab) in Advanced CTCL (EHA 2026)

BioInvent to Present Clinical Data on FcγRIIB Antibody BI-1206 Triplet Combination Therapy with rituximab and Calquence(R) in Relapsed/Refractory NHL at EHA 2026

Ensysce Biosciences Announces Expansion of Patent Protection for Groundbreaking MPAR(R) Overdose Protection Technology

Quarterly Report Q1 2026: Orviglance(R) Approaching Transformative Milestones

Theralase(R) Announces $4 Million Brokered LIFE Offering

Ryder CEO to Address Bank of America Securities Industrials, Transportation, and Airlines Key Leaders Conference

Videolar

No Data

Press-relizlar

BioInvent's TNFR2 Antibody BI-1808 Shows Strong Activity and Immune Activation as Single Agent and in Combination with KEYTRUDA(R) (pembrolizumab) in Advanced CTCL (EHA 2026)

Ensysce Biosciences Announces Expansion of Patent Protection for Groundbreaking MPAR(R) Overdose Protection Technology

Quarterly Report Q1 2026: Orviglance(R) Approaching Transformative Milestones

Theralase(R) Announces $4 Million Brokered LIFE Offering

Search stocks

Ryder System, Inc. (R)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Ryder System, Inc. (R)

Ryder System, Inc. (R) Presents at Bank of America 33rd Annual Industrials, Transportation and Airlines Key Leaders Conference Transcript

BioInvent's TNFR2 Antibody BI-1808 Shows Strong Activity and Immune Activation as Single Agent and in Combination with KEYTRUDA(R) (pembrolizumab) in Advanced CTCL (EHA 2026)

BioInvent to Present Clinical Data on FcγRIIB Antibody BI-1206 Triplet Combination Therapy with rituximab and Calquence(R) in Relapsed/Refractory NHL at EHA 2026

Ensysce Biosciences Announces Expansion of Patent Protection for Groundbreaking MPAR(R) Overdose Protection Technology

Quarterly Report Q1 2026: Orviglance(R) Approaching Transformative Milestones

Theralase(R) Announces $4 Million Brokered LIFE Offering

Ryder CEO to Address Bank of America Securities Industrials, Transportation, and Airlines Key Leaders Conference

Videolar

No Data

Press-relizlar

BioInvent's TNFR2 Antibody BI-1808 Shows Strong Activity and Immune Activation as Single Agent and in Combination with KEYTRUDA(R) (pembrolizumab) in Advanced CTCL (EHA 2026)

Ensysce Biosciences Announces Expansion of Patent Protection for Groundbreaking MPAR(R) Overdose Protection Technology

Quarterly Report Q1 2026: Orviglance(R) Approaching Transformative Milestones

Theralase(R) Announces $4 Million Brokered LIFE Offering

Ryder System, Inc. (R) Presents at Bank of America 33rd Annual Industrials, Transportation and Airlines Key Leaders Conference Transcript

BioInvent's TNFR2 Antibody BI-1808 Shows Strong Activity and Immune Activation as Single Agent and in Combination with KEYTRUDA(R) (pembrolizumab) in Advanced CTCL (EHA 2026)

BioInvent to Present Clinical Data on FcγRIIB Antibody BI-1206 Triplet Combination Therapy with rituximab and Calquence(R) in Relapsed/Refractory NHL at EHA 2026

Ensysce Biosciences Announces Expansion of Patent Protection for Groundbreaking MPAR(R) Overdose Protection Technology

Quarterly Report Q1 2026: Orviglance(R) Approaching Transformative Milestones

Theralase(R) Announces $4 Million Brokered LIFE Offering

Ryder CEO to Address Bank of America Securities Industrials, Transportation, and Airlines Key Leaders Conference

Videolar

No Data

Press-relizlar

BioInvent's TNFR2 Antibody BI-1808 Shows Strong Activity and Immune Activation as Single Agent and in Combination with KEYTRUDA(R) (pembrolizumab) in Advanced CTCL (EHA 2026)

Ensysce Biosciences Announces Expansion of Patent Protection for Groundbreaking MPAR(R) Overdose Protection Technology

Quarterly Report Q1 2026: Orviglance(R) Approaching Transformative Milestones

Theralase(R) Announces $4 Million Brokered LIFE Offering